Loading...
SANION logo

Saniona AB (publ)OM:SANION Stock Report

Market Cap SEK 2.4b
Share Price
SEK 17.66
n/a
1Y147.0%
7D10.7%
Portfolio Value
​
View

Saniona AB (publ)

OM:SANION Stock Report

Market Cap: SEK 2.4b

Saniona (SANION) Stock Overview

A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. More details

SANION fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 98.6% below our estimate of its fair value

Became profitable this year

Risk Analysis

Volatile share price over the past 3 months compared to the Swedish market

Shareholders have been diluted in the past year


SANION Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Saniona AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Saniona
Historical stock prices
Current Share PriceSEK 17.66
52 Week HighSEK 17.92
52 Week LowSEK 5.41
Beta1.2
1 Month Change19.32%
3 Month Change33.79%
1 Year Change146.99%
3 Year Change389.88%
5 Year Change-20.81%
Change since IPO242.91%

Recent News & Updates

There's No Escaping Saniona AB (publ)'s (STO:SANION) Muted Revenues Despite A 32% Share Price Rise

Oct 19
There's No Escaping Saniona AB (publ)'s (STO:SANION) Muted Revenues Despite A 32% Share Price Rise

Recent updates

There's No Escaping Saniona AB (publ)'s (STO:SANION) Muted Revenues Despite A 32% Share Price Rise

Oct 19
There's No Escaping Saniona AB (publ)'s (STO:SANION) Muted Revenues Despite A 32% Share Price Rise

Saniona AB (publ) (STO:SANION) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Aug 21
Saniona AB (publ) (STO:SANION) Surges 45% Yet Its Low P/S Is No Reason For Excitement

Improved Revenues Required Before Saniona AB (publ) (STO:SANION) Stock's 37% Jump Looks Justified

Jun 19
Improved Revenues Required Before Saniona AB (publ) (STO:SANION) Stock's 37% Jump Looks Justified

Increases to Saniona AB (publ)'s (STO:SANION) CEO Compensation Might Cool off for now

May 22
Increases to Saniona AB (publ)'s (STO:SANION) CEO Compensation Might Cool off for now

Saniona AB (publ)'s (STO:SANION) 28% Dip In Price Shows Sentiment Is Matching Revenues

Mar 13
Saniona AB (publ)'s (STO:SANION) 28% Dip In Price Shows Sentiment Is Matching Revenues

Is Saniona (STO:SANION) Using Debt Sensibly?

Nov 06
Is Saniona (STO:SANION) Using Debt Sensibly?

Is Saniona (STO:SANION) Weighed On By Its Debt Load?

Jul 30
Is Saniona (STO:SANION) Weighed On By Its Debt Load?

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Nov 29
Saniona (STO:SANION) Is Making Moderate Use Of Debt

Is Saniona (STO:SANION) Using Too Much Debt?

Aug 16
Is Saniona (STO:SANION) Using Too Much Debt?

Is Saniona (STO:SANION) Using Too Much Debt?

Mar 17
Is Saniona (STO:SANION) Using Too Much Debt?

Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

Feb 10
Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

Jan 06
What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

Is Saniona (STO:SANION) Using Too Much Debt?

Dec 02
Is Saniona (STO:SANION) Using Too Much Debt?

Shareholder Returns

SANIONSE BiotechsSE Market
7D10.7%3.2%3.3%
1Y147.0%-1.5%4.1%

Return vs Industry: SANION exceeded the Swedish Biotechs industry which returned -1.5% over the past year.

Return vs Market: SANION exceeded the Swedish Market which returned 4.1% over the past year.

Price Volatility

Is SANION's price volatile compared to industry and market?
SANION volatility
SANION Average Weekly Movement9.2%
Biotechs Industry Average Movement7.8%
Market Average Movement5.8%
10% most volatile stocks in SE Market11.8%
10% least volatile stocks in SE Market3.1%

Stable Share Price: SANION's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: SANION's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
201131Thomas Feldthuswww.saniona.com

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome; and ACP-711, a positive allosteric modulator of GABAA a3 containing receptors that has completed Phase 1 clinical trial for the treatment of essential tremor, a neurological disorder.

Saniona AB (publ) Fundamentals Summary

How do Saniona's earnings and revenue compare to its market cap?
SANION fundamental statistics
Market capSEK 2.44b
Earnings (TTM)SEK 573.47m
Revenue (TTM)SEK 743.21m
4.3x
P/E Ratio
3.3x
P/S Ratio

Is SANION overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SANION income statement (TTM)
RevenueSEK 743.21m
Cost of RevenueSEK 5.22m
Gross ProfitSEK 737.98m
Other ExpensesSEK 164.51m
EarningsSEK 573.47m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Feb 26, 2026

Earnings per share (EPS)4.15
Gross Margin99.30%
Net Profit Margin77.16%
Debt/Equity Ratio0%

How did SANION perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/29 23:51
End of Day Share Price 2025/11/28 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Saniona AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael NovodNordea Markets
Jesper IlsoeNordea Markets
Fredrik ThorRedeye